Candel announces Nature publication: CAN-3110 extends survival in recurrent high-grade glioma

Candel Therapeutics, Inc.

Phase 1 trial (n=41) of CAN-3110 in recurrent HGG showed median OS of 11.6 months, nearly double historical 6-9 months.
HSV-1 seropositive patients had median OS 14.2 months vs 7.8 months for seronegative; seroconversion linked to improved survival.
Treatment well tolerated with no dose-limiting toxicity; increased immune cell infiltration and T-cell repertoire diversity observed.
Arm C will evaluate up to six injections of CAN-3110, supported by Break Through Cancer foundation.
Publication in Nature titled 'Clinical trial links oncolytic immunoactivation to survival in glioblastoma'.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.